en · de · es · fr · pt
thymosin-alpha-1-notes.peptides6908.com › News › Molecular Identity Of Thymosin Alpha-1 — Explained

Molecular Identity Of Thymosin Alpha-1 — Explained

By Editorial Desk · published 2025-10-29 · last reviewed 2025-11-20 · News

Everything below concerns freeze-thaw cycling. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-11-20. Where a claim depends on a specific study, the study is described rather than over-claimed.

Molecular Identity Of Thymosin Alpha-1

Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.

Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.

Molecular Background and Immune Action

Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.

Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.

Thymosin-alpha-1 at a glance

PropertyValueNotes
ClassSynthetic peptide28 residues; not a small-molecule compound
Molecular massAbout 3,106 DaMonoisotopic mass of the unmodified chain
N-terminal groupAcetylated serinePresent in both native and synthetic forms
Secondary structureDisulfide-constrained loopOne bridge between two cysteine residues
Typical sourceSolid-phase synthesisEarly isolates came from bovine thymus extracts

Molecular Background and Identity

Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.

Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.

Related pages on this site

Background, Structure, and Mechanism

Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.

Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.

Handling, Storage, and Analytical Verification

Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.

Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.

Background and Molecular Identity

Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.

Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.

Reference notes

In this bilateral Snowflake, whitish opacities appear throughout the cornea. The stromal lamellae are abnormal and may be separated by amorphous deposits. Moderate to severe vision loss may occur due to corneal opacity. In case of severe vision loss, treatment of choice is penetrating keratoplasty. Peters anomaly: Peters anomaly, also known as iridocorneal adhesions or keratolenticular adhesions, is a posterior corneal defect with an overlying stromal opacity, often accompanied by adherent iris strands (Peters anomaly type 1). The size and density of the opacity can range from a mild to dense central leukoma. Congenital anterior staphyloma: Congenital anterior staphyloma is a rare form of anterior segment dysgenesis that shares similarities with Peters anomaly. It is characterized by an ectatic protrusion of a central opacified cornea lined by uveal tissue. The protrusion extends beyond the plane of the eyelid margins and it can be unilateral or bilateral. Lattice corneal dystrophy: Lattice corneal dystrophy is an autosomal-dominant characterized by amyloid deposition in the corneal stroma. Due to deposits, lattice-like corneal opacities may occur in stroma. Three types of dystrophies are there, type 1, type 2 and type 3. Type 1 is also known as Biber-Haab-Dimmer corneal dystrophy, TGFBI type Lattice Dystrophy, or Classic Lattice Dystrophy. LCD type II is not included in corneal dystrophies. Granular corneal dystrophy: Two types, Type 1 and Type 2 are there. Both have autosomal dominant inheritance.

The nephritic syndrome is characterised by blood in the urine (especially Red blood cell casts with dysmorphic red blood cells) and a decrease in the amount of urine in the presence of hypertension. In this syndrome, inflammatory damage to cells lining the glomerulus are thought to result in destruction of the epithelial barrier, leading to blood being found in the urine. At the same time, reactive changes, e.g. proliferation of mesangial cells, may result in a decrease in kidney blood flow, resulting in a decrease in the production of urine. The renin–angiotensin system may be subsequently activated, because of the decrease in perfusion of juxtaglomerular apparatus, which may result in hypertension.

=== Isotope preparation === Curium is made in small amounts in nuclear reactors, and by now only kilograms of 242Cm and 244Cm have been accumulated, and grams or even milligrams for heavier isotopes. Hence the high price of curium, which has been quoted at 160–185 USD per milligram, with a more recent estimate at US$2,000/g for 242Cm and US$170/g for 244Cm. In nuclear reactors, curium is formed from 238U in a series of nuclear reactions. In the first chain, 238U captures a neutron and converts into 239U, which via β− decay transforms into 239Np and 239Pu.

Specialty drugs, a recent classification of pharmaceuticals, are high-cost drugs that are often biologics. The European Medicines Agency uses the term advanced therapy medicinal products (ATMPs) for medicines for human use that are "based on genes, cells, or tissue engineering", including gene therapy medicines, somatic-cell therapy medicines, tissue-engineered medicines, and combinations thereof. Within EMA contexts, the term advanced therapies refers specifically to ATMPs, although that term is rather nonspecific outside those contexts. Gene-based and cellular biologics, for example, often are at the forefront of biomedicine and biomedical research, and may be used to treat a variety of medical conditions for which no other treatments are available. Building on the market approvals and sales of recombinant virus-based biopharmaceuticals for veterinary and human medicine, the use of engineered plant viruses has been proposed to enhance crop performance and promote sustainable production. In some jurisdictions, biologics are regulated via different pathways from other small molecule drugs and medical devices.

Sources: en.wikipedia.org

Reference notes

This increased demand is met by an increase in the stroke volume of the octopus' heart. The octopus does sometimes swim throughout the water, exposing itself completely. In doing so, it uses a jet mechanism that involves creating a much higher pressure in its mantle cavity that allows it to propel itself through the water. As the common octopus' heart and gills are located within its mantle, this high pressure also constricts and puts constraints on the various vessels that are returning blood to the heart. Ultimately, this creates circulation issues and is not a sustainable form of transportation, as the octopus cannot attain an oxygen intake that can balance the metabolic demands of maximum exertion.

Lingual antimicrobial peptide (LAP) is a beta-defensin found in bovine internal epithelial tissue, in particular, that of the digestive tract. It has antimicrobial activity against many different pathogens. It was first isolated from an inflamed cattle tongue, hence its designation as lingual. Since then it has been found more extensively throughout the body; its presence has even been detected in bovine milk. Its expression is selective and increases in inflamed areas. LAP may have a closer relationship with immune response than simple antimicrobial activity, such as an association with growth factor activity.

718 Other derangement of joint 718.0 Articular cartilage disorder 718.1 Loose body in joint 718.2 Pathological dislocation 718.3 Recurrent dislocation of joint 718.4 Contracture of joint 718.5 Ankylosis of joint 718.6 Unspecified intrapelvic protrusion of acetabulum 718.7 Developmental dislocation of joint 719 Other and unspecified disorders of joint 719.0 Effusion/swelling of joint, unspec. 719.1 Hemarthrosis 719.2 Villonodular synovitis 719.3 Palindromic rheumatism 719.4 Joint pain, unspec. 719.5 Stiffness of joint 719.7 Difficulty in walking

==== Particles ==== Particles in UPW have always presented a major problem for semiconductor manufacture, as any particle landing on a silicon wafer can bridge the gap between the electrical pathways in the semiconductor circuitry. Particle count can be monitored in ultrapure water using laser-based particle counting systems or, for diagnostics, scanning electron microscopy.

=== Zhejiang === In October 2002, Xi left Fujian and became the deputy governor, acting governor and deputy Party secretary of neighbouring Zhejiang. He eventually took over as provincial Party Committee secretary after the 16th Party National Congress, occupying a top provincial office for the first time in his career. In November 2002, he was elected a full member of the 16th Central Committee by the 16th Party National Congress, marking his ascension to the national stage. While in Zhejiang, Xi presided over reported growth rates averaging 14% per year. During this period, Zhejiang increasingly transitioned away from heavy industry. Xi's career in Zhejiang was marked by a tough and straightforward stance against corrupt officials. This earned him a name in the national media and drew the attention of China's top leaders. Between 2004 and 2007, Li Qiang acted as Xi's chief of staff through his position as secretary-general of the Zhejiang Party Committee, where they developed close mutual ties. During this period, Xi and Li drafted the Double Eight Strategy, which listed eight comparative advantages of Zhejiang and eight corresponding actions to improve the province.

Sources: en.wikipedia.org

Reference notes

Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe. As of 2020, the company had approximately 48,000 employees, and it generated more than $7.7 billion in revenue in 2019. The company offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders, COVID-19, and employment and court-ordered drug testing.

The adrenergic receptors were discovered Henry Hallett Dale in 1906 and the α- and β-adrenergic receptors were differentiated by Raymond P. Ahlquist in 1948. In 1967, the β-adrenergic receptors were further differentiated into the β1- and β2-adrenergic receptors by Alonzo M. Lands. The first beta blocker to be developed was dichloroisoprenaline, based on structural modification of the β-adrenergic receptor agonist isoprenaline (isoproterenol). It was described by C. E. Powell and I. H. Slater in 1958. However, dichloroisoprenaline had significant partial agonism and sympathomimetic activity and hence was not a pure antagonist. James Black and John Stephenson described pronethalol (nethalide; ICI-38,174; Alderlin) as a purely antagonistic beta blocker in 1962. But pronethalol suffered from off-target activity and associated side effects and toxicity. As such, it did not enter widespread use and was soon discontinued. In 1964, Black and colleagues published on propranolol (ICI-45,520; Inderal), which did not have the problems of earlier beta blockers. It was introduced for medical use under the brand name Inderal the same year and became the first widely used beta blocker. Since the introduction of propranolol, there have been three generations of beta blockers with different pharmacological properties, with numerous beta blockers having been developed and introduced for medical use.

=== Lung toxicity === Pulmonary toxicity, or toxicity to lungs, is a serious complication associated with sirolimus therapy, especially in the case of lung transplants. The mechanism of the interstitial pneumonitis caused by sirolimus and other macrolide mTOR inhibitors is unclear, and may have nothing to do with the mTOR pathway. The interstitial pneumonitis is not dose-dependent, but is more common in patients with underlying lung disease.

=== Anthropogenic arsenic compounds === Anthropogenic (man-made) sources of arsenic, like the natural sources, are mainly arsenic oxides and the associated anions. Man-made sources of arsenic, include wastes from mineral processing, swine and poultry farms. For example, many ores, especially sulfide minerals, are contaminated with arsenic, which is released in roasting (burning in air). In such processing, arsenide is converted to arsenic trioxide, which is volatile at high temperatures and is released into the atmosphere. Poultry and swine farms make heavy use of the organoarsenic compound roxarsone as an antibiotic in feed. Some wood is treated with copper arsenates as a preservative. The mechanisms by which these sources affect "downstream" living organisms remains uncertain but are probably diverse. One commonly cited pathway involves methylation. The monomethylated acid, methanearsonic acid (CH3AsO(OH)2), is a precursor to fungicides (tradename Neoasozin) in the cultivation of rice and cotton. Derivatives of phenylarsonic acid (C6H5AsO(OH)2) are used as feed additives for livestock, including 4-hydroxy-3-nitrobenzenearsonic acid (3-NHPAA or Roxarsone), ureidophenylarsonic acid, and p-arsanilic acid. These applications are controversial as they introduce soluble forms of arsenic into the environment.

Since its half-life of 5.5 to 26 hours is quite long, consciousness would take a long time to return. In veterinary medicine, sodium thiopental is used to induce anesthesia in animals. Since it is redistributed to fat, certain lean breeds of dogs such as sighthounds have prolonged recoveries from sodium thiopental due to their lack of body fat. Conversely, obese animals recover rapidly, but it takes much longer for the drug to be entirely removed (metabolized) from their bodies. Sodium thiopental is always administered intravenously, as it can be fairly irritating to tissue and is a vesicant; severe tissue necrosis and sloughing can occur if it is injected incorrectly into the tissue around a vein.

Sources: en.wikipedia.org

Frequently asked questions

Is this peptide found naturally in the body?

Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.

Why is the disulfide bridge important?

The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.

How does it differ from other thymic peptides?

It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.

What is thymosin alpha 1 made of?

It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.

Network